Snapshot
Phase I oncology trials rarely give teams the luxury of time. Cohorts shift. Dosing strategies evolve. Visit schedules change. In that environment, the last thing a study team feels they need is technology that adds friction instead of reducing it. Traditional eCOA implementations have often felt unnecessary or oversized for Phase I realities.
There's no regulatory requirement driving the need for eCOA in Phase I oncology trials. Agency guidance on collecting PRO/COA data to evaluate quality of life (QoL) gets specific in Phase II and III, once efficacy and tolerability data are required. In Phase I, the focus is more on dose escalation, toxicity, and safety, so it’s rare that clinical science teams are asking why you don't have an eCOA vendor lined up.
The result is that sponsors and biotechs don't tend to use eCOA in early phase. Not because the data wouldn't help, but because it’s not common practice, it's not required, and cost and setup hassle make paper (or nothing) the path of least resistance. That can be a rational call in the moment with the pressures these teams face. It's also a mindset carried over from thinking about eCOA as a Phase II/III commitment, not something you can right-size for Phase I.
That's the mindset I think we can challenge. The value of tracking patients’ QoL doesn't start at Phase II. Patients in Phase I may be dealing with just as much disease burden or QoL impacts or improvements. There is value in being able to capture that information and carry it later phases as your compound advances.
Suvoda’s Oncology Assessment Package is a flat-fee, Phase I-tailored way to start. It is an eCOA solution designed specifically for Phase I oncology and delivered in combination with Suvoda RTSM/IRT, with a scope matched to what these studies most commonly need: in-clinic data collection on patient's own devices (BYOD (bring-your-own-device)—no required provisioned hardware to manage) and a set of commonly used standard questionnaires like the EORTC QLQ-C30.
The scope is an intentional feature, not a limitation. Phase I oncology studies don’t typically require broad customization from the start. They need a reliable, efficient way to capture outcomes electronically, without the cost and configuration overhead of a full eCOA system. When studies require more, like translations, localization, additional questionnaires, or provisioned devices, those can be added.
The result is an implementation model that fits the operational reality of early phase work: fast to stand up, easy for sites to use, and directly connected to Suvoda RTSM—a system purpose-built for the dose escalation decisions, cohort management, and eligibility complexity that define Phase I oncology.
If your compound is likely to advance to further investigation, the value of this data compounds too. You're not starting from zero when Phase II or III makes eCOA a requirement instead of a choice.
Phase I studies can be especially demanding for sites and patients. Sites manage dose escalation decisions, cohort transitions, and eligibility criteria that can shift with every cycle. Patients may have frequent clinic visits, sometimes multiple times per week. Managing this complexity with paper assessments or disconnected systems can become cumbersome for everyone, quickly.
In early phase oncology, the relationship between assessment data and treatment decisions is close and consequential. How a patient responds to treatment affects dosing. Visit activity shapes which assessments are due. Eligibility draws on multiple data streams at once. When eCOA operates separately from RTSM, teams lose that coherence. Data lives in separate places, reconciliation challenges arise, and the real-time picture that could support faster decisions stays fragmented. That gap matters most in Phase I, where protocol amendments are common and the window for acting on new information is narrow.
When both technologies are unified such as on the Suvoda Platform, assessment data and treatment logistics stay synchronized. Eligibility is informed more efficiently. Teams gain a connected view of each patient that supports confident decisions when it matters most.
There is a longer-term benefit to using eCOA in Phase I trials. Teams that begin collecting outcomes electronically in Phase I arrive at later-phase development with hands-on experience, established workflows, and a technology foundation already integrated with their RTSM environment. Phase II and Phase III oncology trials carry significantly greater eCOA complexity, and the sponsors and trial teams who become familiar with eCOA earlier may have a head start at navigating that complexity because they aren’t learning the technology alongside other trial activities.
The Suvoda Oncology Assessment Package is one way to begin that journey without overextending in Phase I. It supports the current study and, as phases advance, scales with them.
Early phase oncology is demanding by nature. The technology supporting it should reduce that burden, not add to it. The Suvoda Oncology Assessment Package was designed for exactly that: eCOA and RTSM operating as one, right-sized for Phase I, and ready to scale as programs advance.
Andrés Escallón
Vice President, eCOA
Solutions Strategy,
Suvoda